Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Thromboangiitis Obliterans (TAO)

Thromboangitis obliterans (TAO), also known as Buerger's disease, is a rare blood vessel disease. With our proficient team of researchers and scientists specializing in thromboangiitis obliterans, we drive innovation in diagnostic tools and therapeutic drugs. As your trusted partner, we provide tailored and comprehensive services to meet your specific scientific research needs.

Overview of Thromboangiitis Obliterans

Thromboangiitis obliterans is a vascular condition characterized by inflammatory thrombosis occurring in small and medium-sized arteries, as well as certain superficial veins. This condition primarily affects the distal extremities and results in arterial ischemia and superficial thrombophlebitis. Thromboangiitis obliterans has a relatively low incidence, with an estimated prevalence of around 4 to 9 cases per 100,000 individuals.

Thromboangiitis obliterans is characterized by distinct pathophysiological phases.Fig. 1 Pathophysiological phases of thromboangiitis obliterans. (Piazza, Gregory, and Mark A. Creager., 2010)

Pathogenesis of Thromboangiitis Obliterans

The primary risk factor for thromboangiitis obliterans is smoking, and the disease is infrequently observed in individuals who do not smoke. The precise mechanism by which smoking induces thromboangiitis obliterans is not completely understood. Several theories propose that tobacco may elicit an immune response in susceptible individuals or may expose coagulation defects, both of which can initiate an inflammatory reaction within the walls of blood vessels.

Strategies of Thromboangiitis Obliterans Therapy Development

Inhibit Inflammatory Response

The immune-induced inflammatory response is a critical characteristic of thromboangiitis obliterans. Potential drug candidates can be developed by targeting specific molecules involved in inflammatory response pathways, such as tumor necrosis factor-α (TNF-α) or interleukin-6 (IL-6). Immunomodulators like corticosteroids and methotrexate, for instance, suppress the inflammatory response and mitigate immune cell activation.

Restore Endothelial Function

Endothelial dysfunction is a hallmark of thromboangiitis obliterans and plays a crucial role in the disease process. Vascular endothelial dysfunction leads to impaired vasodilation, increased expression of adhesion molecules, and enhanced platelet activation. Prostacyclin analogs, such as iloprost and treprostinil, act as vasodilators and platelet inhibitors to improve blood flow and prevent thrombosis.

Our Services

Drawing upon our deep expertise in biotechnology and extensive experience in the industry, our company offers all-encompassing solutions for diagnostic and therapeutic research dedicated to thromboangiitis obliterans.

Induced Models
Vascular inflammation is a hallmark of thromboangiitis obliterans. Our scientists have successfully induced vascular inflammatory responses in animals by administering pro-inflammatory agents such as lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha). These models faithfully reproduce features associated with human thromboangiitis obliterans.
Surgical Models
Thrombosis and subsequent vascular occlusion are key pathological features of thromboangiitis obliterans. To replicate these aspects in animal models, our researchers use techniques such as ligation or surgical placement of constriction devices to induce vessel occlusion.
Optional Species Mice, Rats, Rabbits, Non-Human Primates (Baboons and Macaques), Others

No matter what stage of research you are at, we can provide you with corresponding research services. If you are interested in our services, please feel free to contact us for more details and quotation information for related services.


  • Piazza, Gregory, and Mark A. Creager. "Thromboangiitis obliterans." Circulation 121.16 (2010): 1858-1861.
  • Li, Meng-di, et al. "Risk factors, mechanisms and treatments of thromboangiitis obliterans: an overview of recent research." Current Medicinal Chemistry 27.35 (2020): 6057-6072.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.